Kornimate/medical-research-clean huggingface dataset:
necrotizing bacterial dermohypodermitis-necrotizing fasciitis mono- or multi-microbial streptococcus beta-haemolytic

Conditions: Streptococcus Infection

Summary: the aim of the study is to evaluate streptococcal carriage by swab, pharyngeal, anal and perineal in patients with dhbn-fn, in the entourage living under the same roof as well as patients with erysipelas the main hypothesis is the major role of chronic porting of patients and entourage in dhbn-fn to sbh. indeed, the chronic pharyngeal / anal / perineal carriage could be a gateway following a transient bacteremia for a dhbn-fn. the transmission of germs from the surrounding to the patient plays a major role: at the gateway level in the case of exogenous dhbn-fn at the origin of chronic carriage in the case of endogenous dhbn-fn transmission of germs from the patient to the surrounding area also plays an important role in increasing the risk of invasive sbh infections in the surrounding area.


Eligibility criteria:
inclusion criteria: * patient: * major patient hospitalized for a dhbn-fn or erysipelas (clinical diagnosis determined at the entrance). * signed informed consent. case contact * person of major age living under the same roof as a patient who has had a dhbn-fn. * signed informed consent exclusion criteria: * patient: * minor patient * immunosuppressed patient: active hematology, poorly controlled hiv, neutropenia (pnn \<1000 / mm3). * patient under guardianship or curatorship * patient deprived of liberty by judicial or administrative decision * patient not affiliated to a social security scheme and not a beneficiary of such a scheme case contact * minor person * person under tutorship or curatorship * person deprived of liberty by judicial or administrative decision * person not affiliated with a social security
study of the change of breast cancer patients' upper limb lymphatic drainage pathway after operation

Conditions: Lymphedema of Upper Arm

Summary: lymphoscintigraphy is a noninvasive，accurate and effective imaging modality. in this study, it is used to investigate the imaging characteristics of patients'upper limb lymphatic drainage before operation, and the influence of operation on it.

the global burden of breast cancer continues to increase largely because of the aging and growth of the world population. more than 1.38 million women worldwide were estimated to be diagnosed with breast cancer in 2008, accounting for 23% of all diagnosed cancers in women. given that the 5-year survival rate for breast cancer is now 90%, experiencing breast cancer is ultimately about quality of life. women treated for breast cancer are facing a life-time risk of developing lymphedema, a chronic condition that occurs in up to 40% of this population and negatively affects breast cancer survivors' quality of life. it's becoming more and more important to do more research on the breast cancer-related lymphedema. axillary reverse mapping (arm) is a technique used to map arm lymphatic drainage during axillary lymph node dissection (alnd) and/or sentinel lymph node dissection (slnd). it's necessary for the investigators to understand the participants' upper limb lymphatic drainage before operation and what the investigators have done on it during operation. it can be easy to understand the influence of operation on the participants' upper limb lymphatic drainage, the possibility and safety of reserving lymph nodes draining the upper extremity lymph.

Eligibility criteria:
inclusion criteria: for inclusion in the study patients must fulfil all of the following criteria: 1. diagnosed with breast cancer 2. there is no metastasis except axillary nodes 3. agree to receive lymphoscintigraphy of upper extremity exclusion criteria: any of the following is regarded as a criterion for exclusion from the study: 1. pregnancy or lactation 2. inflammatory breast cancer 3. disagree to receive lymphoscintigraphy of upper extremity 4. history of axillary lymph node resection

Keywords: lymphedema of upper arm breast cancer breast cancer-related lymphedema lymphoscintigraphy
ec95 of remifentanil for preventing cough

Conditions: Drug Usage

Summary: the investigator designed this study to investigate remifentanil effect-site concentration in 95% of patients (ec95) for preventing cough after laryngomicrosurgery from propofol anesthesia.

at the end of the surgery, propofol infusion was stopped and remifentanil was titrated to predetermined (initial concentration 1.0 ng/ml for the first patient). extubation was performed when the patients opened their eyes and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed.

Eligibility criteria:
inclusion criteria: * asa i-ii patients undergoing general anesthesia for laryngomicrosurgery exclusion criteria: * anticipated difficult airway * copd, asthma * recent uri (\< 2 weeks) * severe cardiac, hepatic renal disease

Keywords: extubation remifentanil laryngomicrosurgery
the impact of myofascial release therapy on dysphagia in post-stroke patients

Conditions: Dysphagia

Summary: the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic stroke survivors. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in stroke survivors? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

myofascial release, also known as fascial release or fascial manipulation, is a physical therapy used to treat muscle and fascial tissue tension or pain. it involves applying appropriate pressure and stretching to release tight fascia and soft tissues, improving blood circulation, alleviating pain, and promoting rehabilitation. the goal of this clinical trial is to explore clinical effect of myofascial release therapy in dysphagic stroke survivors. the main question it aims to answer is: • can myofascial release therapy improve swallowing function in stroke survivors? patients will be randomly allocated into the control group or the experimental group, all under rehabilitation treatment, the experimental group will be given myofascial release therapy. the study lasts 21 days for each patient. researchers will compare the functional oral intake scale, penetration-aspiration scale, swallowing quality of life to see if the myofascial release therapy can help improve the situation.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years; * meeting the diagnostic criteria of stroke; * any degree of dysphagia at admission; * steady vital signs, without severe cognitive impairment or sensory aphasia, able to cooperate with the assessment. * transferred out within three weeks of hospitalization in the neurology department. exclusion criteria: * complicated with other neurological diseases; * damaged mucosa or incomplete structure in nasopharynx; * tracheostomy tube plugged; * unfeasible to myofascial release; * simultaneously suffering from liver, kidney failure, tumors, or hematological diseases.
a phase ii trial of adjuvant radiotherapy combined with chemotherapy for patients with high-risk endometrial cancer

Conditions: Prosthesis Survival

Summary: this phase ii clinical trial was designed to assess the feasibility, safety, toxicity, recurrence and survival pattern when tp or cap chemotherapy was combined with adjuvant radiation for patients with high-risk endometrial cancer.


Eligibility criteria:
inclusion criteria: * patients must have had a hysterectomy (total abdominal, vaginal hysterectomy, or laparoscopic-assisted vaginal hysterectomy) or modified radical hysterectomy or radical hysterectomy and bilateral salpingo-oophorectomy no more than 8 weeks prior to start of radiation therapy. additional surgical staging procedures are permissible but not required. * risk factors: patients must fit one of the following: * pelvic lymph node metastases * paraaortic lymph node metastases * grade 3 with myometrial invasion \>50% * with stromal invasion of cervix * known extrauterine disease (excluding second primary) confined to the pelvis. * high risk pathological type include: uterine papillary serous carcinoma, clear cell carcinoma, squamous cell carcinoma, undifferentiated carcinoma, * no known gross residual disease, or distant metastases. * eastern cooperative oncology group (ecog) score\<=2; age 18\~75. * white blood cell (wbc)≥4000/mm3, granulocytes ≥1500/mcl, platelets≥100,000/mcl. * acceptable hepatic and renal function: creatinine \<=1.4 mg%, bilirubin and serum glutamate oxaloacetate transaminase (sgot) \<=2\*normal. * no medical contraindications to chemotherapy, or radiation therapy. * study-specific signed informed consent. exclusion criteria: * prior pelvic radiation therapy. * positive peritoneal cytology only for stage iiia (figo 1998). * with history of other malignancies less than 5 years. * with gross residual disease, or distant metastases. * with endometrioid endometrial carcinoma and no risk factors: * with myometrial invasion \<50% * grade 1\~2, with myometrial invasion \>50% * with serious internal diseases which affect designed treatment * with psychotic disorders

Keywords: disease free survival, overall survival
open label study of postmenopausal women with er and /or pgr positive breast cancer treated with letrozole

Conditions: Breast Cancer

Summary: to evaluate safety and efficacy (measured by clinical tumor response) of letrozole daily dose, 2.5 mg in postmenopausal patients with primary (untreated) breast cancer.


Eligibility criteria:
inclusion criteria: 1. postmenopausal woman able to comply with the protocol requirements with primary invasive breast cancer, histologically confirmed by core needle biopsy, whose tumors are estrogen (er) and / or progesterone (pgr) positive, defined by core biopsy immunohistochemistry with \> 10% positive malignant epithelial cells. 2. clinical stage \*t2, t3, t4a,b,c, n0, 1 or 2, m0 * clinical stage t2 tumors which in the investigators opinion would not be eligible for breast-conserving surgery. 3. post menopausal status defined by one of the following: * no spontaneous menses for at least 1 year, in women \> 55 years. * spontaneous menses within the past 1 year but amenorrhoeic in women ≤ 55 years (e.g. spontaneous or secondary to hysterectomy), and with postmenopausal gonadotrophin levels (lh y fsh levels \> 40 iu/l) or postmenopausal estradiol levels (\< 5 ng/dl) or according to the definition of "postmenopausal range" for the laboratory involved. * bilateral oophorectomy. (prior to the diagnosis of breast cancer). 4. tumor measurable by clinical examination, mammography and ultrasound. exclusion criteria: 1. prior treatment with letrozole or tamoxifen. 2. uncontrolled endocrine disorders such as diabetes mellitus, confirmed hypo- or hyperthyroidism, cushing's syndrome, addison's disease (treated or untreated). 3. patients with unstable, angina, or uncontrolled cardiac disease (e.g. class iii or iv new york heart association's functional classification). 4. patients with bilateral breast tumors 5. patients who are eligible for breast conserving surgery 6. evidence of inflammatory breast cancer or distant metastasis. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: breast cancer, er and/or pgr positive, letrozole
weight change with controlled ankle movement (cam) walker boot use

Conditions: Foot Injury; Ankle Injury

Summary: the purpose of the study is to determine if patients wearing a cam walker boot have a change in weight compared to patients who wear a cam boot and are provided nutritional and upper body exercise information.

the study objectives are: (1) determine if patients wearing a cam (controlled ankle movement) walker boot have a change in weight compared to patients who wear a cam boot and are provided nutritional and upper body exercises (gender appropriate) information at the time the cam boot is dispensed; and (2) determine, if weight is gained or lost, the average amount gained/lost over the treatment period.

Eligibility criteria:
inclusion criteria: * age greater or equal to 18 (male or female) * participants prescribed a cam boot as standard of care from the study investigator's practice * participant willing to have weight measured at the clinic site at time of enrollment and final visit * participants willing to have blood drawn for albumin level at beginning and end of study * participant is able to provide voluntary, written informed consent * participant, in the opinion of the clinical investigator, is able to understand the clinical investigation and is willing to perform all study procedures and follow-up visits. * fluent in written and spoken english exclusion criteria: * participants less than 18 years of age * pregnant women * cognitive impairment * participants with vertigo or other balance issues * participants unable to provide informed consent * non-english speaking individuals * participants who will not be wearing a cam boot for at least 6 weeks * participants unable/unwilling to perform upper body exercises and follow nutrition guidelines

Keywords: adult cam boot controlled ankle movement
extension study to evaluate the long-term outcomes of pediatric patients who received treatment for retinopathy of prematurity in the vgfte-rop-1920 study (acronym: butterfleye next)

Conditions: Retinopathy of Prematurity

Summary: primary objectives of the study are: * to evaluate binocular visual acuity at the end of this study in patients included from the vgfte-rop-1920 study, for treatment of retinopathy of prematurity (rop). * to evaluate long-term safety outcomes in patients included from the vgfte-rop-1920 study, for treatment of rop. secondary objectives of the study are: * to describe visual function in patients included from the vgfte-rop-1920 study, for treatment of rop. * to describe overall development in patients included from the vgfte-rop-1920 study, for treatment of rop.


Eligibility criteria:
inclusion criteria: 1. patient was treated in study vgfte-rop-1920 2. age \<13 months of chronological age 3. signed informed consent from parent(s)/legal guardian(s), which includes compliance with the requirements and restrictions listed in the informed consent form (icf) and in this protocol exclusion criteria: 1. patient has a condition preventing participation in the study, or performance of study procedures note: other inclusion/exclusion criteria may apply
biomarkers of prednisolone treatment (p05888)

Conditions: Insulin Resistance; Hyperglycemia; Glucose Intolerance

Summary: primary objective: * to identify a biomarker or biomarker-set for the adverse metabolic effects of various doses of prednisolone treatment. secondary objectives: * to describe the pk of prednisolone and pd of a series of biomarkers. * to identify biomarkers that reflect side effects of prednisolone. * to elucidate part of the mechanisms by which prednisolone induces metabolic changes.


Eligibility criteria:
inclusion criteria: * 22 \< bmi \< 30 * fasting glucose \< 5.6 mmol/l and glucose \< 7.8 mmol/l 2hr after ogtt * able and willing to sign informed consent * history of good physical and mental health * subject smokes less than 5 cigarettes per day * able to keep a normal day and night rhythm exclusion criteria: * allergy to prednisolone * glucocorticoid use during last 3 months prior to study * use of any drug or substance * history of familiar diabetes type 2 * clinically relevant history or presence of any medical disorder * clinically relevant abnormal lab or ecg * positive drug or alcohol screen, positive hepatitis b or c surface antigen * donation of blood (\>100 ml) within 90 days prior to the first dose

Keywords: prednisolone glucocorticoids
visual field progression and rnfl change after preserflo microshunt implantation

Conditions: Glaucoma; Progression; Surgery

Summary: the trabeculectomy is the gold standard in glaucoma surgery, nevertheless often postoperative interventions have to be done. (1),(2) the preserflo microshunt (santen, osaka, japan) implantation occurs without critical steps of trabeculectomy. (3) according to a study a 20% eye pressure reduction was achieved in 53.9% of patients one year after preserflo microshunt implantation and the risk of postoperative hypotony was clearly minimized. (4) it has been shown that after trabeculectomy there is a stable development of visual fields in the first 3 months after surgery and then, despite adequate intraocular pressure reduction, visual fields deteriorate. (5) at the klinikum klagenfurt structural and functional changes after preserflo microshunt implantation shall be evaluated.


Eligibility criteria:
inclusion criteria: * patients with insufficient eye pressure control despite iop (intraocular pressure)-lowering therapy * diagnosis of poag (primary open angle glaucoma) * diagnosis of peg (pseudoexfoliation glaucoma) * diagnosis of pdg (pigment dispersion glaucoma) * diagnosis of ntg (normal tension glaucoma) * agreement of patients to participate in the study exclusion criteria: * previous glaucoma surgery * visual acuity of nulla lux * poor general condition * pregnancy * exudative macular degeneration
a study of sbrt for oligometastatic escc

Conditions: Esophageal Squamous Cell Carcinoma Metastatic

Summary: the aim of this phase ii trial is to assess progress-free survival, local control, overall survival, safety and tolerability of sbrt to treat patients with oligometastases in esophageal squamous cell carcinoma.


Eligibility criteria:
inclusion criteria: 1. patients with metastatic esophageal squamous cell carcinoma who have received initial treatment for the primary site including surgery or chemoradiotherapy. primary tumor site without progression at registration. the sites of allowed metastases are: peripheral lung, central lung, medistinal/cervical lymph node, liver, spinal/paraspinal, osseous, and abdominal-pelvic lymph node. all metastases not resected must be amenable to sbrt. 2. 1-4 radiographically distinct metastases of any distribution in 2 or less allowed anatomical sites. the diameters of lesions should be less than or equal to 5cm. 3. initial treatment should be completed at least 3 months prior to study registration. 4. all the metastases treated with sbrt should not be treated with surgery, radiation, radio frequency ablation or other regional therapeutic modalities prior to study registration. the other (s) lesions should have been surgically removed. 5. age ≥ 18. ps ecog 0-2，wight loss\<30% during the latest 6 months. 6. evaluation by a radiation oncologist that the patient could tolerate the treatment of sbrt. 7. patient must provide study specific informed consent prior to study entry. 8. for females of child-bearing potential, negative serum/urine pregnancy test within 14 days prior to study registration. exclusion criteria: 1. progression of primary tumor site at time of registration. 2. metastases with indistinct borders making targeting not feasible. 3. known brain metastases. 4. prior palliative radiotherapy to metastases. 5. metastases located within 3 cm of the previously irradiated structures: a).spinal cord previously irradiated \>80gy(biological equivalent dose with α/β=2), b).brachial plexus previously irradiated to \> 100gy(biological equivalent dose with α/β=2), c).small intestine, large intestine, or stomach previously irradiated to \> 90gy (biological equivalent dose with α/β=2), d).whole lung previously irradiated with prior v20gy \> 30% (delivered in ≤ 3 gy/fraction), e)metastasis irradiated with sbrt. 6. pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives. 7. drug addiction,alcoholism or aids. 8. patients with severe organ dysfunction or acute bacterial or fungal infection who are considered not suitable to enroll the study at the time of registration.
emotional freedom technique (eft) effect on nurses

Conditions: Anxiety, Covid-19 Fear

Summary: it has been planned to determine the effect of eft, which effectiveness has been determined by the studies, on the covid-19 fear and anxiety experienced by the nurses working in the emergency department. the study was designed as a randomized controlled study with pre-test and post-test control group.

although it has been a year since who declared an emergency, the covid-19 virus has mutated and the number of cases has started to increase again as of february 2021. the emergence of uncertainties in the risk of transmission of the mutant virus together with the simultaneous management of both the care process of pandemic patients and the patients who apply for emergency care and treatment in the emergency services increases the fear of the virus. the feeling of fear causes the person to become distracted and increase anxiety by focusing on the fact that he or she is under the threat of the virus. recently, non-pharmacological techniques are widely used to reduce anxiety and fear. one of them is eft. it is to examine the effects of eft, which effectiveness has been determined with the studies carried out in this challenging process, on the covid-19 fear and high anxiety of emergency room nurses.

Eligibility criteria:
inclusion criteria: * not taking any courses about coping with anxiety and stress, * volunteering to participate in the study, * the absence of infection, wound, scar in the tapping area exclusion criteria: * having any psychiatric diagnoses
comparison between type a botulinum toxin injection and corticosteroid injection in the treatment of tennis elbow

Conditions: Type A Botulinum Toxin; Tennis Elbow

Summary: humeral lateral epicondylitis or tennis elbow is a common painful elbow disorder. the cause of tennis elbow is the chronic overload of bone-tendon junction. high prevalence of tennis elbow has a direct impact on the workplace productivity and quality of life. steroid injection is the very few methods proved to have short-term efficacy in tennis elbow treatment, but it has potential adverse effects like tendon rupture. temporary paralysis of muscle after botulinum toxin injection may reduce the physical demands and facilitate the normal repair mechanism during recovery. preliminary studies suggested that botulinum toxin injection is effective in treating tennis elbow. the objective of this study is to compare the effects of botulinum toxin injection with corticosteroid injection in tennis elbow treatment.


Eligibility criteria:
inclusion criteria: * pain at the lateral epicondyle of the elbow * tenderness at the lateral epicondyle of the elbow * pain on resisted extension of the wrist exclusion criteria: * local injection of steroid within 3 months * previous elbow trauma or operations * pregnancy * systemic neuromuscular disorders such as myasthenia gravis
an open label study of nls-2 (mazindol extended release) in subjects with narcolepsy

Conditions: Narcolepsy With Cataplexy; Narcolepsy; Narcolepsy Without Cataplexy

Summary: this is a multicenter, open-label extension of the clinical study nls-1021, evaluating long-term safety, tolerability, pharmacokinetics (pk), and therapeutic response to treatment with nls-2 in adult subjects with narcolepsy.


Eligibility criteria:
inclusion criteria: * the subject must complete all study nls-1021 study requirements and assessments up to visit 6; * the subject is able, in the opinion of the investigator, to receive nls-2 for the 24-week treatment phase of this study; * biological females of childbearing potential must agree to use a medically acceptable double-barrier method of contraception for at least 30 days prior to day 1 and until completion of the study; * the subject is able to comply with the open-labelled extension design schedule and other study requirements; * the subject provides written informed consent for the open-label extension study. exclusion criteria: * the subject meets any exclusion criteria for study nls-1021 at visit 6 of that study; * the subject receives any investigational drug (other than the covid-19 vaccine) that is not nls-2.